1. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. (November 2018) Authors: Hurvitz, S.A.; Quek, R.G.W.; Turner, N.C.; Telli, M.L.; Rugo, H.S.; Mailliez, A.; Ettl, J.; Grischke, E.; Mina, L.A.; Balmaña, J.; Fasching, P.A.; Bhattacharyya, H.; Hannah, A.L.; Robson, M.E.; Wardley, A.M. Journal: European journal of cancer Issue: Volume 104(2018) Page Start: 160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗